GSK Awarded Up To $200M For Bioterror Drug Program

Law360, New York (May 22, 2013, 1:23 PM EDT) -- The U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority said Wednesday it has awarded GlaxoSmithKline PLC up to $200 million in a groundbreaking effort to help develop new drugs to fight antibiotic resistance and bioterrorism.

BARDA said the agreement, under which the drugs will be developed under a public-private partnership agreement between GSK and the U.S., is the first time HHS has taken a portfolio approach with a private-sector company instead of contracting to develop a single medical countermeasure — a...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.